Skip to content

Patricia
Wongsodirdjo

PhD candidate
The Florey · The University of Melbourne

My research explores mRNA-encoded antibodies as an alternative means to deliver antibodies for Alzheimer’s disease. I am dedicated to improving patient outcomes and treatment accessibility.

In my PhD, I’m developing brain delivery vehicles to enhance the uptake of mRNA-encoded antibodies in the brain for Alzheimer’s disease.

At The Florey in Melbourne, wearing a burgundy floral blouse.
At The Florey, Melbourne.

Exploring mRNA as an Alternative Platform for Antibody Delivery

In my first-author study, we used mRNA to produce antibodies that recognise tau, a protein that clumps into toxic aggregates in Alzheimer’s disease. The animation shows how the mRNA-encoded antibody fragment is made intracellularly and engages with tau.

See the cell experiments ↓

The cell receives mRNA.

I used synthetic mRNA encoding RNJ1, an antibody that recognises tau. In the cytoplasm, the cell’s protein-making machinery reads this mRNA.

A ribosome reads the mRNA.

A ribosome reads the mRNA from its 5′ end towards its 3′ end, building the protein chain that will form the antibody fragment.

The fragment folds into an intrabody.

The RNJ1 fragment has variable heavy and light domains joined by a flexible linker. These fold into a single-chain variable fragment (scFv) that can bind tau inside the cell.

The intrabody binds tau.

RNJ1 recognises tau’s N-terminus. In our human cell experiments, we detected expression of the mRNA-encoded intrabody and its engagement with intracellular tau.

Illustrated RNJ1 scFv mechanism in human SH-SY5Y cells. Our findings are in Brain Communications (2024).

Recent Publications

Publications & presentations
In the laboratory at The Florey.

What Drives My Research

My grandmother and great-aunt were both affected by Alzheimer's disease, and I witnessed firsthand the devastating impact it can have on those we love. Their experiences have deeply shaped my motivation to pursue Alzheimer's research. In honour of their legacies, I am driven to contribute to the development of novel therapeutics for Alzheimer's disease in the Antibody Therapeutics Group at The Florey, under the guidance of my supervisors, A/Prof Rebecca Nisbet and A/Prof Laura Vella.

More about me